Zobrazeno 1 - 10
of 421
pro vyhledávání: '"Bryan T. Hennessy"'
Autor:
Gavin P. Dowling, Sinead Toomey, Philip Bredin, Imelda Parker, Eibhlin Mulroe, Jacinta Marron, Olivia McLoughlin, Ausra Teiserskiene, Colm Power, Anne Marie O’Shea, Megan Greally, Patrick G. Morris, Deirdre Duke, Arnold D. K. Hill, Bryan T. Hennessy
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted therapies have significan
Externí odkaz:
https://doaj.org/article/525da2fab1674ea289c10763a6526868
Autor:
Nicola Cosgrove, Alex J. Eustace, Peter O’Donovan, Stephen F. Madden, Bruce Moran, John Crown, Brian Moulton, Patrick G. Morris, Liam Grogan, Oscar Breathnach, Colm Power, Michael Allen, Janice M. Walshe, Arnold D. Hill, Anna Blümel, Darren O’Connor, Sudipto Das, Małgorzata Milewska, Joanna Fay, Elaine Kay, Sinead Toomey, Bryan T. Hennessy, Simon J. Furney
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments i
Externí odkaz:
https://doaj.org/article/2aa94f4a6ce8446ea48464a6049912d0
Autor:
Cha Len Lee, Mattia Cremona, Angela Farrelly, Julie A. Workman, Sean Kennedy, Razia Aslam, Aoife Carr, Stephen Madden, Brian O’Neill, Bryan T. Hennessy, Sinead Toomey
Publikováno v:
Cancer Biology & Therapy, Vol 24, Iss 1 (2023)
Background Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 inhibitor) in colorectal cancer (CRC), however single agent therapeutics are often limited by the devel
Externí odkaz:
https://doaj.org/article/d6504dd8615048a28a9b44cb8dd1ecfd
Autor:
Valentina Thomas, Ahmed Rashed, Clare Faul, Siobhan Nicholson, Vincent Young, John Hanson, Bryan T. Hennessy, Sinead Toomey, Simon J. Furney
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 3, p 257 (2024)
Up to 15% of lung cancer patients present two or more anatomically separate primary lung lesions, known as multiple primary lung cancers (MPLCs). While surgical resection or stereotactic body radiation therapy (SBRT) is the standard of care for most
Externí odkaz:
https://doaj.org/article/7f1c4cd5ad634909bcc5756c90f21850
Autor:
Gavin P. Dowling, Stephen Keelan, Sinead Toomey, Gordon R. Daly, Bryan T. Hennessy, Arnold D. K. Hill
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PurposeThe development of human epidermal growth factor receptor 2 (HER2)-directed therapies has revolutionized the treatment of HER2-positive breast cancer. The aim of this article is to review the continually evolving treatment strategies in the ne
Externí odkaz:
https://doaj.org/article/6a03b95135c141528bd2fbe1e3202046
Autor:
Cathy E. Richards, Yasir Y. Elamin, Aoife Carr, Kathy Gately, Shereen Rafee, Mattia Cremona, Emer Hanrahan, Robert Smyth, Daniel Ryan, Ross K. Morgan, Susan Kennedy, Lance Hudson, Joanna Fay, Kenneth O’Byrne, Bryan T. Hennessy, Sinead Toomey
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 10545 (2023)
PTPN11 encodes the SHP2 protein tyrosine phosphatase that activates the mitogen-activated protein kinase (MAPK) pathway upstream of KRAS and MEK. PTPN11/Shp2 somatic mutations occur frequently in Juvenile myelomonocytic leukaemia (JMML); however, the
Externí odkaz:
https://doaj.org/article/6dfb1fbd27d14df4ba344828c1f6dcc5
Autor:
M. Janusz Mezynski, Angela M. Farrelly, Mattia Cremona, Aoife Carr, Clare Morgan, Julie Workman, Paul Armstrong, Jennifer McAuley, Stephen Madden, Joanna Fay, Katherine M. Sheehan, Elaine W. Kay, Ciara Holohan, Yasir Elamin, Shereen Rafee, Patrick G. Morris, Oscar Breathnach, Liam Grogan, Bryan T. Hennessy, Sinead Toomey
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-16 (2021)
Abstract Background Aberrant PI3K signalling is implicated in trastuzumab resistance in HER2-positive gastric cancer (GC). The role of PI3K or MEK inhibitors in sensitising HER2-positive GCs to trastuzumab or in overcoming trastuzumab resistance is u
Externí odkaz:
https://doaj.org/article/d5312ba8bd22456eb68ea89c9e9a8189
Autor:
Rachel J. Keogh, Razia Aslam, Maeve A. Hennessy, Zac Coyne, Bryan T. Hennessy, Oscar S. Breathnach, Liam Grogan, Patrick G. Morris
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG). However, 1 year of PCV is associated with significant toxicities. In the pivotal RTO
Externí odkaz:
https://doaj.org/article/8a8e86d631dc496780b61a82416dbf04
Autor:
Roshni D. Kalachand, Ciaran O’Riain, Sinead Toomey, Aoife Carr, Kirsten M. Timms, Sharon O’Toole, Stephen Madden, Mark Bates, John J. O’Leary, Noreen Gleeson, Dearbhaile O’Donnell, Liam Grogan, Oscar Breathnach, Angela Farrelly, Britta Stordal, Bryan T. Hennessy
Publikováno v:
Obstetrics & Gynecology Science, Vol 63, Iss 5, Pp 643-654 (2020)
Objective The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to evaluate BRCA1/2 defects in tubal/ovarian cancer (OC). We sought to determine the pattern and disease characteristics associated with tumor BRCA1/2 mut
Externí odkaz:
https://doaj.org/article/6cbb4fc095ea435da4eec3de790092e5
Autor:
Damien Kaukonen, Riina Kaukonen, Lélia Polit, Bryan T. Hennessy, Riikka Lund, Stephen F. Madden
Publikováno v:
BMC Medical Genomics, Vol 13, Iss 1, Pp 1-14 (2020)
Abstract Background The role of histone modifications is poorly characterized in breast cancer, especially within the major subtypes. While epigenetic modifications may enhance the adaptability of a cell to both therapy and the surrounding environmen
Externí odkaz:
https://doaj.org/article/88654745956846bfa203762cb13d93ae